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Introduction
Parkinson’s disease (PD) is a progressive disorder of  the CNS that is primarily associated with impaired 
movement. PD likely develops over decades and is linked to the gradual loss of  dopamine delivery to the 
striatum, predominantly via the loss of  dopaminergic (DA) neurons in the substantia nigra pars compacta 
(SNpc) (1). In spite of  intense research, PD etiology largely remains a mystery. In a minority of  cases 
though, the characterization of  familial forms has opened avenues into understanding PD pathophysiolo-
gy. Among the handful of  mutations linked to familial PD forms is a glycine-to-serine change at position 
2019 (G2019S) in leucine-rich repeat kinase 2 (LRRK2 [also known as PARK8]). LRRK2G2019S is linked to 
hyperkinase activity (2) and phosphorylation of  Rab proteins (3). LRRK2G2019S is found in approximately 
30% of  PD cases in North African Berbers and is the most common cause of  late-onset, autosomal dom-
inant, familial, and sporadic PD (4). LRRK2 is a multifunctional 285-kDa protein that contains a serine/
threonine kinase domain, a GTPase domain, and protein-protein interaction domains (2, 5–8). LRRK2 is 
expressed in brain areas receiving DA innervation, such as the striatum, hippocampus, cortex, cerebellum, 
substantia nigra (SN), and ventral tegmental area (9–11).
Understanding the effect of  LRRK2G2019S has been challenging because most LRRK2G2019S-express-
ing animals do not recapitulate many of  the histological and behavioral hallmarks of  PD (12, 13). An 
alternative to transgenesis is to deliver expression cassettes containing disease-associated cDNAs into the 
brain using viral vectors. In some cases, the vector should preferentially transduce neurons, allow long-term 
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease among the 
elderly. To understand its pathogenesis and to test therapies, animal models that faithfully 
reproduce key pathological PD hallmarks are needed. As a prelude to developing a model of PD, we 
tested the tropism, efficacy, biodistribution, and transcriptional effect of canine adenovirus type 
2 (CAV-2) vectors in the brain of Microcebus murinus, a nonhuman primate that naturally develops 
neurodegenerative lesions. We show that introducing helper-dependent (HD) CAV-2 vectors results 
in long-term, neuron-specific expression at the injection site and in afferent nuclei. Although HD 
CAV-2 vector injection induced a modest transcriptional response, no significant adaptive immune 
response was generated. We then generated and tested HD CAV-2 vectors expressing leucine-rich 
repeat kinase 2 (LRRK2) and LRRK2 carrying a G2019S mutation (LRRK2G2019S), which is linked to 
sporadic and familial autosomal dominant forms of PD. We show that HD-LRRK2G2019S expression 
induced parkinsonian-like motor symptoms and histological features in less than 4 months.
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expression, distribute vector genomes to distal regions via axonal transport, be produced at high titers, and 
have a large cloning capacity. The last issue is essential in the case of  LRRK2, whose cDNA is approxi-
mately 8 kbp. Helper-dependent (HD) canine adenovirus type 2 (CAV-2) vectors satisfy these and other 
criteria (14). For example, CAV-2 vectors preferentially transduce neurons from numerous species, includ-
ing mice, rats, and dogs; additionally, in humans, CAV-2 vectors preferentially transduce neurons grown 
in 2D cultures, 3D neurospheres, and organotypic slices of  cortical tissue (14–17). Following injection in 
the rodent and dog striatum, CAV-2 axonal transport into structures/neurons that project into the injection 
site is remarkably efficient (14–16). Notably, DA neurons in the rodent SNpc also express CAV-2–encoded 
foreign protein and normal cellular proteins for >1 year after injection (16–18).
As a prelude to developing a model of  PD, we assayed the tropism, efficacy, transcriptional effect, and 
biodistribution of  HD CAV-2 vectors in the striatum of  Microcebus murinus. M. murinus is a nonhuman 
primate (NHP) that is readily bred in captivity, can live >10 years, and naturally shows some age-related 
signs of  neurodegenerative diseases (19–23). We show that CAV-2 vectors lead to long-term, neuron-spe-
cific expression at the site of  injection as well as in the ipsilateral and contralateral frontal cortex, SNpc, 
thalamus, and other regions. CAV-2 tropism and retrograde transport was consistent with the engagement 
of  coxsackievirus and adenovirus receptor (CAR, ref. 24) at the presynapse (24–31). To test the potential 
of  CAV-2 vectors to model PD, we generated vectors harboring 10-kbp expression cassettes containing 
LRRK2 or LRRK2G2019S. We show that LRRK2G2019S expression in the M. murinus brain can induce parkin-
sonian-like motor symptoms and histological lesions in less than 4 months, thus allowing evaluation of  PD 
pathobiology, compounding factors, progression, and/or therapies.
Results
Preferential and widespread neuron transduction in the NHP brain. To test CAV-2 vector efficacy in the NHP 
brain, we unilaterally injected the M. murinus caudate nucleus with a HD vector expressing GFP (HD-GFP) 
(see Table 1 for details). At the indicated times, the animals were sacrificed and the brains were processed 
for GFP expression, immunohistochemistry, transcriptome analyses, and/or used to extract DNA. Fif-
ty-micron-thick sections were screened by confocal microscopy to identify and quantify transduced cells 
throughout the CNS. At the injection site we found a dense concentration of  GFP+ soma and processes 
(Figure 1A). GFP+ cell bodies and neurites were also present throughout the frontal (Figure 1, B and C) and 
occipital cortices (Figure 1D) in both hemispheres, in the SNpc of  the injected hemisphere (Figure 1E), in 
the ipsilateral basal nuclei of  Meynert (Figure 1F), and in other regions (Figure 1G). The dense GFP signal 
surrounding the injection site is consistent with transduction of  striatal neurons and GFP-filled axons of  
neurons projecting therein. In a minority of  animals, the GFP pattern suggested that some vector leaked 
into the ventricles/cerebral spinal fluid and transduced cells lining the ventricles (Figure 1G). To provide a 
global view of  the regions transduced by a single injection of  HD-GFP, we created a 3D image of  the M. 
murinus brain and highlight areas that contained transduced cells (Figure 1H).
To identify the GFP+ cells, we stained sections with antibodies that preferentially identify neurons (anti-
NeuN) or astrocytes (anti–glial fibrillary acidic protein [anti-GFAP]). We found that CAV-2 vectors prefer-
entially transduced neurons (>90%) at the injection site (Figure 2A). Colabeling with tyrosine hydroxylase 
(TH) demonstrated that some GFP+ cells located in the SN were DA neurons (Figure 2B). To semiquantify 
HD-GFP transduction efficacy following striatal injection, we manually counted GFP+ cells throughout 
the parenchyma in animals killed at 2 weeks (n = 2), 2 months (n = 1), or 6 months (n = 1) (Table 2). While 
the number of  animals/point was too small for statistical analyses, the data suggest that the total number of  
GFP+ neurons was at least as robust at 2 weeks as at 6 months. This is particularly relevant in the context 
of  CAV-2 vector immunogenicity and demonstrates that the vectors are amendable to long-term expression 
of  a potentially immunogenic protein (GFP) in the NHP brain. Anecdotally, the two animals that had the 
greatest number of  GFP+ cells were also among the youngest when injected (12 months old). Because we 
were interested in transduction of  neurons in the SNpc, we quantified TH+ and GFP+ neurons in this struc-
ture. Initially, we found that the M. murinus SNpc has approximately 3,000 TH+ neurons/hemisphere (n = 
4 hemispheres). In M. murinus 51 and M. murinus 133, we detected approximately 2,100 GFP+ cells in the 
ipsilateral SNpc (Table 2). These data indicate a transduction efficacy of  approximately 70% TH+ neurons/
hemisphere following a CAV-2 vector deposit at a single coordinate in the caudate nucleus. Together, these 
data demonstrate that CAV-2 vectors preferentially transduce neurons, are transported to afferent structures 
in both hemispheres, and lead to stable expression of  a foreign protein in the NHP brain.
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Table 1. NHPs used in this study




51 M 33 Striatum 3A HD-GFP 15 EF, IHC
55 F 27 Ventricle 1 HD-GFP 15 EF, IHC
57 M 27 Striatum 1 HD-GFP 15 qPCR
64 M 28 Striatum 1 HD-GFP 15 EF, IHC
65 M 28 Striatum 1 HD-GFP 15 qPCR
104 F 8 Ventricle 1 HD-GFP 60 EF, IHC
120 F 12 Striatum 1 HD-GFP 60 EF, IHC
133 M 12 Striatum 1 HD-GFP 180 EF, IHC
139 F 13 Striatum 1 PBS PBS 1 Transcriptome
140 F 13 Striatum 1 PBS PBS 1 Transcriptome
666 F 13 Striatum 1 PBS PBS 1 Transcriptome
680 F 13 Striatum 1 PBS PBS 1 Transcriptome
727 F 13 Striatum 1 PBS HD-GFP 1 Transcriptome
730 F 13 Striatum 1 PBS HD-GFP 1 Transcriptome
733 F 13 Striatum 1 PBS HD-GFP 1 Transcriptome
738 F 13 Striatum 1 PBS HD-GFP 1 Transcriptome
735 F 14 Striatum 1 PBS HD-GFP 28 Transcriptome
739 F 14 Striatum 1 PBS HD-GFP 28 Transcriptome
742 F 14 Striatum 1 PBS HD-GFP 28 Transcriptome
748 F 14 Striatum 1 PBS HD-GFP 28 Transcriptome
777 M 12 Striatum 1 LRRK2G2019S 15 IHC
781 M 12 Striatum 1 LRRK2G2019S 15 IHC
783 M 12 Striatum 1 LRRK2G2019S 180 Behavior, IHC
802 M 12 Striatum 1 LRRK2G2019S 180 Behavior, IHC
805 M 12 Striatum 1 LRRK2G2019S 180 Behavior, IHC
809 M 12 Striatum 1 LRRK2G2019S 180 Behavior, IHC
849 M 12 Striatum 1 LRRK2G2019S 180 Behavior, HPLC, 
IHC
852 M 12 Striatum 1 LRRK2G2019S 180 Behavior, HPLC, 
IHC
857 M 12 Striatum 1 LRRK2G2019S 180 Behavior, HPLC, 
IHC
858 M 12 Striatum 1 LRRK2G2019S 180 Behavior, HPLC, 
IHC
810 M 12 Striatum 1 LRRK2 180 Behavior, IHC
813 M 12 Striatum 1 LRRK2 180 Behavior, IHC
814 M 12 Striatum 1 LRRK2 180 Behavior, IHC
819 M 12 Striatum 1 LRRK2 180 Behavior, IHC
811 M 12 Striatum 1 HD-GFP 180 Behavior, IHC
812 M 12 Striatum 1 HD-GFP 180 Behavior, IHC
838 M 12 Striatum 1 HD-GFP 180 Behavior, HPLC, 
IHC
841 M 12 Striatum 1 HD-GFP 180 Behavior, HPLC, 
IHC
970 M 12 Striatum 1 HD-GFP 180 Behavior, HPLC, 
IHC
971 M 12 Striatum 1 HD-GFP 180 Behavior, HPLC, 
IHC
AIn M. murinus 51, the vector was deposited at 3 coordinates along the same needle track. IHC, immunohistochemistry; HPLC, high-performance liquid 
chromatography; EF, epifluorescence microscopy.
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GFP expression parallels vector biodistribution and CAR expression. The quantification of  GFP+ cells and use of  
3D reconstruction generate a global view of  transgene expression. However, these data do not provide a quan-
titative assessment of  vector biodistribution because each neuron subtype could take up a different quantity of  
vector and, therefore, a single GFP+ cell could have multiple vector genomes. We therefore quantified vector 
genomes in distinct regions of  two animals. Using qPCR on DNA isolated from various brain regions, we 
Figure 1. Expression of GFP following injection of HD-GFP in the M. murinus striatum. The brains from 6 M. murinus, injected at 8–33 months of age (see 
Table 1), were used to determine the efficacy of GFP expression from a helper-dependent (HD) CAV-2 vector (HD-GFP). (A) Injection site. Juxtaposed images 
showing the caudate nucleus (Cd), internal capsule (IC), nucleus accumbens (Acc), and anterior commissural (AC). (B) Ipsilateral prefrontal cortex (4 images 
juxtaposed). (C) Ipsilateral pyriform cortex. (D) Contralateral frontal cortex (cell bodies are located in the second and fourth cortical layers). (E) Substantia 
nigra (VIII). (F) Basal nucleus of Meynert (central-medial nucleus [CEM]). (G) Thalamic nuclei: periventricular nucleus (Pa), nucleus parataenialis (Pt), stria 
medullaris (Sm), anterior-medial nucleus (Am). (H) 3D reconstruction of the brain showing distribution of the GFP signal in both hemispheres following 
injection into the caudate nucleus. Images in A, C, F, and G are from M. murinus 133, which was sacrificed 6 months after injection. Scale bar: 200 μm.
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found that the highest number of  vector genomes was in the basal forebrain, which corresponds to the injec-
tion site (Table 3). Notable levels of  vectors were also found in the adjacent structures, such as the temporal 
and parietal cortices, the thalamus, and the midbrain. Fewer HD-GFP genomes were found in the prefrontal 
and occipital cortices, the cerebellum of the injected hemisphere, and in the olfactory bulb. Globally, vector 
genome biodistribution in M. murinus 65 mirrors GFP expression pattern in M. murinus 64.
Ex vivo and in the rodent brain, CAV-2 engagement of  CAR leads to neuron binding, internalization, 
and retrograde transport (24–31). To determine if  the CAR expression pattern was consistent with CAV-2 
tropism in the primate brain, we screened brains for CAR expression by immunoblotting and immunoflu-
orescence. We found that CAR was readily detected in several regions of  the M. murinus brain by immu-
noblotting (Figure 3A). However, for CAV-2 to be transported from the injection site to the soma of  cells 
in other regions, CAR would need to be expressed on axonal projections. Consistent with our results in 
rodents (28), CAR was present in the synaptosome fraction in extracts of  the M. murinus brain (Figure 3B). 
Using immunofluorescent staining of  adult M. murinus brain sections, we found that CAR was expressed 
by neurons in the SNpc, cortex, and thalamus — regions that project into the caudate nucleus (Figure 3C). 
Together, these data suggest a physiological explanation for CAV-2 tropism and biodistribution via CAR 
engagement and axonal transport in a NHP brain.
Effect of  CAV-2 vectors on the brain transcriptome. We previously showed that the transcriptional profile 
of  human neurons grown in 2D and 3D cultures is differentially modified following interaction with HD 
human adenovirus type 5, lentivirus, and HD CAV-2 vectors (32). To address the transcriptional response 
in the more complex in vivo environment, we quantified changes in mRNA levels following HD-GFP 
versus PBS injection in the M. murinus caudate nucleus at 1 and 28 days after injection. We quantified 
Figure 2. Identification of HD-GFP–transduced cells in the M. murinus brain. Sections from M. murinus brains (n = 6 animals) were stained for neuronal 
and astrocytes specific markers to identify transduced cells. (A) Representative image from the injection site, caudate nucleus, showing GFP, glial fibrillary 
acidic protein (GFAP), and NeuN (neuronal nuclei antigen) expression followed by merged images. (B) Representative image from the substantia nigra (SN) 
showing GFP and tyrosine hydroxylase (TH) expression, followed by merged images. Scale bars: 100 μm (A, top) and 25 μm (A, bottom); and 100 μm (B).
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transcriptional changes in the dorsal region of  the frontal lobe, the striatum, and the midbrain (Figure 4 
and Supplemental Tables 1 and 2; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.98202DS1). Twenty samples were analyzed for each brain to take into account the 
variation in time after injection and the regions from each hemisphere.
At 1 day after injection, transcriptional changes were detected in the 3 structures. By comparing 
sham-operated controls, injected caudate nuclei, and the contralateral caudate nuclei, we identified the dif-
ferential expression of  17 genes in the striatum, 19 in the dorsal frontal lobe, and 40 in the midbrain (Sup-
plemental Figure 1 and Supplemental Table 1). Overall, our analyses showed that vector injection induced 
transcriptional changes in genes involved in innate immunity, intracellular trafficking, and transcriptional 
regulations in the striatum. The transcriptional changes in the noninjected structures are consistent with the 
fast (~2 μm/s) retrograde transport of  CAV-2 (31) to these regions. At 28 days after injection, approximate-
ly 100 genes were differentially expressed in each structure (Supplemental Table 2). In the injected striatum, 
13 of  the 19 modified transcripts suggested an initiation of  an adaptive immune response. In contrast to 
those in the striatum, the transcripts in the frontal lobe of  the injected hemisphere were similar to those 
found at day 1. In the midbrain of  the injected hemisphere, 45 genes involved in a variety of  functions, 
including trafficking and signaling, were differentially expressed. These data suggest that the transcriptional 
changes were linked to GFP expression.
Hierarchical clustering was used to identify gene families that changed in the frontal lobe, stria-
tum, and midbrain as a function of  the time after injection. Importantly, each group of  genes displayed 
a distinct profile depending on the structure and the time after injection (Figure 4). Again, this pattern 
parallels the retrograde transport of  HD-GFP from the caudate nucleus and the expression of  GFP. 
We then applied a principal component analysis (PCA) to find patterns in the 6 groups (2 times × 
3 structures) (Supplemental Tables 1 and 2). We found that two principal components were able to 
explain approximately 85% of  the total information in the injected and left frontal cortex, 88% in the 
injected striatum, 73% in the contralateral striatum, and approximately 80% in the right and left mid-
brain. The variance inside each group did not result in an overlap among the groups, consistent with 
the different response following vector injection. This transcriptional profile suggests that HD-GFP 
injections may have induced an aborted innate immune response immediately after injection. Impor-
tantly, neurons are very poor antigen-presenting cells and cannot, to the best of  current knowledge, 
initiate a T cell response (33). Because we see GFP expression for at least 6 months, this is consistent 
with the lack of  an efficient vector- or transgene-specific immune response.
Table 2. Quantification of GFP+ cells following injection of HD-GFP in the M. murinus
Ipsilateral Injected Contralateral Total
M. murinus Duration Injection sites TE DE ME
Ctx BE
51 2 weeks Striatum 15,700 7,400 3,500 2,100 28,700 6,400 35,100
64 2 weeks Striatum 2,700 1,400 200 1,200 5,500 2,000 7,500
120 2 months Striatum 24,000 16,900 50 750 41,700 2,400 49,600
133 6 months Striatum 23,400 13,400 7,400 2,200 46,400 6,300 52,700
TE, telencephalon; Ctx, cortex; BE, basal encephalon; DE, diencephalon; ME, midbrain.
 
Table 3. Quantification of vector genomes following injection of HD-GFP in the M. murinus caudate nucleus







57 2 371,200 5,500 98,800 131,200 106,700 29,000 2,100
65 2 657,700 8,000 144,400 232,100 130,000 143,200 4,100
TE, telencephalon; pFCtx, prefrontal cortex; Ctx, cortex; Str, striatum; DE, diencephalon; ME, midbrain
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LRRK2G2019S expression leads to parkinsonian-like motor symptoms in M. murinus. The above data provid-
ed an impetus for modeling PD in M. murinus. We therefore generated HD CAV-2 vectors expressing 
LRRK2 (HD-LRRK2) or LRRK2G2019S (HD-LRRK2G2019S) (see Supplemental Figure 2A for schema of  
vector). Initially, two animals were injected in the caudate nucleus with HD-LRRK2G2019S and killed 
15 days after injection, and brain sections were incubated with anti-LRRK2 antibodies. We detected 
LRRK2 immunoreactivity in cells with neuron-like morphology in the injected hemisphere (Supple-
mental Figure 2B). By contrast, the rare LRRK2-immunoreactive cells in the contralateral hemisphere 
had astrocyte-like morphology. Interestingly, there was also a global and homogenous Iba1 and BRCA1 
immunoreactivity throughout the injected caudate nucleus and putamen at 15 days after injection (Sup-
plemental Figure 3) that was no longer detectable 6 months after injection. This widespread microglia 
immunoreactivity is inconsistent with a response against the vector injected into the caudate nucleus and 
suggests a LRRK2G2019S-induced microglia response.
Figure 3. Coxsackievirus and adenovirus receptor expression in the M. murinus brain. (A) Immunoblot analyses of coxsackievirus and adenovirus recep-
tor (CAR) from the brains of M. murinus (n = 2 animals). β-Tubulin levels were used to normalize loading. (B) CAR levels in synaptosomes prepared from 
the cortex (n = 2 animals) and assayed for the presence of CAR. As a control, we used synaptophysin, a prototypic synapse protein. (C) CAR expression 
pattern, as assayed by immunofluorescence staining: SN, pyriform cortex, and thalamus (n = 3 animals). The 16-micron-thick floating sections were coin-
cubated an anti-Tuj1 (β-III tubulin) antibody to identify neurons and with DAPI to label nuclei. Scale bar: 50 μm.
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Figure 4. Transcriptional profiles of the most discriminant genes in the striatum, in the frontal lobe, and in the midbrain after HD-GFP injection. Hier-
archical clustering was obtained for each brain region: (A) right frontal cortex; (B) left frontal cortex; (C) injected (right) striatum; (D) contralateral striatum; 
(E) right midbrain; and (F) left midbrain. Each column corresponds to one animal, whereas each row corresponds to one gene (red: overexpressed genes; 
green: downregulated genes; black: genes without expression changes). Principal component analysis (PCA) of the 19–45 genes sorted by SAM or by ANOVA 
for each brain region analyzed. The x axis corresponds to the principal component 1 and the y axis to the principal component 2 (expressed in percentages). 
Projection of the individuals shows that each group of animal can be distinguished from the other irrespective of the brain structure. At the bottom of the 
figure, there is a schematic representation of the M. Murinus brain, indicating vector transport from the injected site, the right striatum, to the contralateral 
side (red hatched arrow), to the frontal cortex (blue arrow), and to the midbrain (green arrow). Brains were collected at 1 or 24 days after injection.
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The cardinal characteristics of  PD are motor deficits, including 
bradykinesia, akinesia, rigidity, and resting tremor. We therefore tai-
lored behavior assays for M. murinus to determine whether LRRK2 or 
LRRK2G2019S expression leads to parkinsonian-like motor symptoms. 
Prior to vector injections, the cohorts were subjected to hourglass, tower, 
and 6-tube tasks to obtain baseline readings (each animal served as its 
own control). Following the training, vectors were injected in the hemi-
sphere controlling their dominant hand. The animals were assayed for 
motor control every week for 6 months after injection.
The hourglass assay consists of  placing the animal in a transpar-
ent cylinder, inverting the cylinder, and measuring the time the animal 
needs to right itself. We found that GFP expression did not affect motor 
coordination compared with baseline performance. However, LRRK2 
expression caused significant (P < 0.05) impairment, with a return to 
baseline scores after month 3 (see Figure 5A for cumulative data and 
Supplemental Figure 4A for group data at each week for 6 months). 
LRRK2G2019S expression induced significant (P < 0.05) delays in the abil-
ity of  the animals to right themselves throughout the trial, and these 
delays were greater (P < 0.05) than those induced by LRRK2 expression.
The tower task consists of  placing the animal at the bottom of  a tow-
er with spiral rungs that are progressively further apart. The incentive to 
climb the rungs is fruit at the top. The performance of  GFP-expressing 
animals was equal to that in their preinjection trials. However, LRRK2 
and LRRK2G2019S expression significantly (P < 0.05) increased the time 
needed to reach the top compared with GFP expression (Figure 5B for 
cumulative data and Supplemental Figure 4B for group data at each 
week for 6 months). Moreover, while LRRK2 expression only caused 
increased climbing times, LRRK2G2019S expression also caused akinetic 
and bradykinetic responses, which resulted in significantly longer climb-
ing times (P < 0.05) compared with those after LRRK2 expression.
The 6-tube task measures unconstrained manual dexterity. During 
the trial, the animal retrieved a raisin from inside 1 of 6 horizontal tubes. 
All animals showed a decreased response (longer times) immediately after 
injection (Supplemental Figure 4C). Thereafter, HD-GFP–injected ani-
mals improved their performance during the trial. By contrast, LRRK2 
and LRRK2G2019S expression led to significantly (P < 0.05) slower recovery 
(Figure 5C). It is worth noting that M. murinus can have a dominant hand 
and that injections were unilateral. In most cases, LRRK2 and LRRK2G2019S 
expression caused animals to use their nondominant hand to retrieve rai-
sins. However, we were unable to accurately quantify these events.
LRRK2G2019S expression leads parkinsonian-like histological anomalies. A key histological hallmark of PD is the 
progressive loss of DA neurons. To determine whether LRRK2 or LRRK2G2019S expression induced the degen-
eration of nigrostriatal DA neurons, we assayed TH immunoreactivity in brain sections from animals that were 
killed 6 months after injection. Compared with the contralateral hemisphere, LRRK2G2019S expression caused a 
striking loss of TH immunoreactivity, dystrophic neurites, and swollen axons in the SNpc of the injected hemi-
sphere (Figure 6, A–F). By comparing the different cohorts, we found that LRRK2 and LRRK2G22019S expression 
Figure 5. Behavior analyses following GFP, LRRK2, or LRRK2G2019S expression. 
(A) Hourglass test (4 GFP-, 4 LRRK2-, and 8 LRRK2G2019S-expressing animals). 
(B) Tower task (6 GFP-, 4 LRRK2-, and 8 LRRK2G2019S-expressing animals). (C) 
Six-tube task (2 GFP-, 4 LRRK2-, and 8 LRRK2G2019S-expressing animals). Data 
are expressed as mean ± SEM. Nonparametric Kruskal-Wallis test: *P < 0.05. 
AU, arbitrary units; LRRK2, leucine-rich repeat kinase 2.
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caused a significant (P < 0.05) decrease in the number of TH+ nigral neurons (Figure 6G).
We then reasoned that, if  the number of  DA neurons were reduced in the injected hemisphere, this should 
correspond to a reduction in the density of  TH+ nerve terminals. We therefore quantified TH immunoreactiv-
ity in sections containing the caudate nucleus and putamen from LRRK2G2019S-expressing animals. Consistent 
with the reduction in DA neurons, we found a significant (P < 0.05) reduction in TH immunoreactivity in the 
injected putamen (Figure 6H), but not in the caudate nucleus (Figure 6I), compared with the contralateral 
Figure 6. Changes in TH cell characteristics following LRRK2G2019S expression. Representative images of (A) tyrosine hydroxylase (TH) immunoreactivity 
(dark brown staining) in a coronal section of the midbrain of LRRK2G2019S-expressing M. murinus (n = 8 animals). High-magnification images of TH+ cell bod-
ies and projections in the hemisphere expressing LRRK2G2019S (left) versus the contralateral hemisphere (right) are shown below. Scale bars: 1 mm (top); 50 
μm (bottom). (B) Swollen neurites and (C) dystrophic neurons due to LRRK2G2019S expression. (D) Neurons in control animals (n = 2). (E) Loss of neurites and 
(F) TH immunoreactivity due to LRRK2G2019S expression. Scale bars: 2.5 mm. (G) Quantification of TH+ cells in the substantia nigra of the LRRK2G2019S-ex-
pressing hemisphere versus controls (n = 3 mock-, 5 HD-GFP–, 7 HD-LRRK2G2019S–, and 4 HD-LRRK2-injected animals). TH+ neurons were quantified by 
counting cells in 1 of every 6 sections. The y axis represents the average number of TH+ neurons/section in all groups. Mann-Whitney test: *P < 0.05. (H) 
optical density of TH immunoreactivity in the putamen (n = 4 animals). (I) Optical density of TH immunoreactivity in the caudate nucleus (n = 3 animals). 
Data in H and I are expressed as mean ± SEM. Nonparametric Kruskal-Wallis test: *P < 0.05. C, caudate nucleus; P, putamen.
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hemisphere. To further examine the effect of  LRRK2G2019S expression on the nigrostriatal DA pathway, the 
levels of  striatal dopamine and its metabolites 3,4-dihydroxyphenylacetic acid, homovanillic acid, 5-hydroxy-
tryptamine, 5-hydroxyindoleacetic acid were quantified. However, LRRK2G2019S expression did not lead to 
lower levels of  dopamine or its metabolites at 6 months after injection (Supplemental Figure 5).
Finally, we asked if  LRRK2G2019S expression (Supplemental Figure 6A) was associated with tau or 
α-synuclein phosphorylation. Compared with contralateral hemispheres, we found increases in α-synucle-
inpS129 and phospho-tauSer396 immunoreactivity following LRRK2G2019S expression at 6 months after injection 
(Supplemental Figure 6, B and C, respectively).
Discussion
Because gene transfer to the human brain will be irreversible, this therapeutic approach creates unique 
challenges — in particular the need to address vector tropism, feasibility, efficacy, safety, and duration 
of  expression. In this study, we evaluated the efficacy of  CAV-2 vectors in the NHP brain as a prelude to 
expressing PD-causing proteins therein. We demonstrated robust transgene expression, duration, and bio-
distribution coupled with minimal transcriptional effect and immunogenicity in the M. murinus brain. Our 
results are also consistent with the use CAR, either on the soma or at the synapse, by CAV-2 to preferential 
infect neurons and be transported to efferent structures (14). We demonstrate that LRRK2G2019S expression 
leads to parkinsonian-like motor deficits and histological lesions, including the loss of  TH+ neurons in the 
SN, a decrease of  the density of  TH+ fibers, the generation of  swollen axons and dystrophic neurons, and 
the phosphorylation of  tau and α-synuclein. We conclude that LRRK2G2019S expression in the M. murinus 
induced PD-associated motor symptoms and histological characteristics.
The M. murinus as a PD model. The lack of  relevant animal models that faithfully recapitulate human 
brain diseases has slowed the development of  therapies. An ideal PD animal model should (a) have a normal 
complement of  DA neurons at birth; (b) have more than 50% of these neurons be selectively and gradually 
lost in adulthood; (c) have motor deficits, preferably bradykinesia, rigidity, and resting tremor; (d) be based 
on a single mutation to allow robust propagation and facilitate crossing with enhancer or suppressor strains; 
and (e) have a disease course of  a few months to allow rapid and inexpensive screening of  therapeutic agents 
(12). Transgenic mice have often disappointed, possibly due to functional compensation during development, 
species-specific differences in disease mechanisms, immune responses, and/or in the anatomical organization 
(34, 35). Differences in general behavior and responses to common cognitive tests also make assays in rodents 
challenging for clinical evaluations. Therefore, studies using NHPs represent a “step to human” where discov-
eries could be readily translated into therapies (22, 36). However, the number of  NHPs available for biomed-
ical research, such as baboons, macaques, or marmosets, is limited, under increased regulatory regulations, 
and expensive (37). Conversely, self-sustaining breeding M. murinus colonies could provide a sufficient num-
ber of  animals for trials that require large numbers to reach statistical significance. The M. murinus is small 
nocturnal primate, that is biologically, behaviorally, and socially much closer to humans than rodents. The M. 
murinus brain also has a structure and organization readily comparable to that of  human brain. M. murinus 
have been maintained and bred successfully in captivity since the 1960s, with life span reaching >10 years; and 
this has contributed to the protection and the biodiversity of  the wild populations. M. murinus reach maturity 
within the first year of  life and have a relative high fecundity for a NHP (gestation, 2 months; 1–3 offspring/
litter; weaning at 2 months; pubertal age, 6–8 months) (37). M. murinus are increasingly used to understand 
aging and Alzheimer’s disease (including amyloid-β vaccination) (38), MRI evaluation of  cerebral atrophy 
(39), and identification of  cognitive deficits (39, 40). In addition, because of  captive breeding programs, M. 
murinus are one of  the few NHPs approved by current European regulation. Finally, while drug-induced PD 
models (e.g., 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or 6-hydroxydopamine) (41, 42) have significantly 
advanced our understanding of  PD, they poorly recapitulate chronic and slow disease progression.
Our primary goals in delivering HD-LRRK2 and HD-LRRK2G2019S were to determine if  overexpression 
leads to parkinsonian-like motor and histological lesions in NHPs. It is clear that the LRRK2G2019S M. murinus 
model fulfills many of  the criteria needed to help advance our understanding of, and develop and validate 
therapies for, PD. Moreover, striatal injection of  CAV-2 vectors could also allow one to better understand the 
complex circuitry in PD: for example, what is the role of  pruning and regrowth of  striatal projecting neurons 
into the basal ganglia? Does pruning and regrowth effect synaptic transmission? We found that unilateral 
injections in the caudate nucleus unexpectedly exhibited some cyclic motor deficits (Supplemental Figure 
4). While unilateral injections allowed for internal comparison between hemispheres, they likely reduced the 
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inception and maintenance of  parkinsonian-like symptoms. It is possible that the cyclic motor deficits were 
due to compensation via the crosstalk between the SN and striata. Given the presence of  cross-hemispheric 
DA neuron projections (43), M. murinus injected with HD-LRRK2G2019S could help address their functional 
significance. In addition, unilateral injections of  HD-LRRK2G2019S may help us understand how the brain 
adapts during PD. For example, can cross-hemispheric DA neurons rescue unilateral striatal dysfunction, as 
suggested by our data? Are cross-hemispheric DA neuron projections more pronounced in primates than in 
rodents? In rats the current estimate is that approximately 5% of the neurons project to the contralateral hemi-
sphere (44). It is reasonable to assume that the percentage is higher in the primate brain.
LRRK2G2019S expression induced parkinsonian-like histological changes in the DA neurons in the SN. It is 
encouraging that LRRK2G2019S expression induced a markedly decreased number of DA cells within 6 months, 
given that the LRRK2G2019S familial form of PD typically does not manifest itself  until the fourth or fifth decade. 
The lack of significant difference in dopamine metabolite concentrations at 6 months after injection could be 
due to compensatory resprouting of the DA neuronal processes from the SNpc or from neurons from other 
nuclei/regions that project to the striatum. Our results are consistent with reports describing the association of  
fragmented axons with axonal spheroids and dystrophic neurites in LRRK2R1441G-transgenic mice (45) and other 
pathological changes in cell body and axons of transgenic mice overexpressing LRRK2G2019S (46). Axon per-
turbation could be due to LRRK2’s role in the regulation of Rab phosphorylation and neurite outgrowth (47).
Although LRRK2G2019S expression appears to be critical for the development of  α-synuclein–induced 
neuropathology in mice, no LRRK2 transgenic model has developed α-synuclein inclusions. These obser-
vations suggest that α-synuclein produced at physiological levels in rodents is not affected by LRRK2 over-
expression (48). Notably though, as primates age they produce greater amounts of  endogenous α-synuclein 
in SN neurons, making them more susceptible to protein aggregates and degeneration. We are unaware 
of  studies that compare endogenous levels of  α-synuclein in rodents and primates. Here, we found that 
LRRK2G2019S expression led to increased α-synucleinpS129 as well as phospho-tauSer396 immunoreactivity. Tau 
binds tubulin to stabilize microtubules and promotes tubulin assembly into microtubules. The maintenance 
of  axon morphology and transport of  molecules and organelles depends on microtubule stabilization by tau, 
and altered tau function could block transport of  organelles, neurofilaments, and vesicles (49). The presence 
of  phospho-tau is a common feature in LRRK2 model systems (45, 47, 50) and is consistent with observa-
tions that LRRK2 mutations can be associated with tauopathies lacking α-synuclein Lewy bodies (51, 52).
CAV-2 vector characteristics. Neurons in distal structures can readily take up CAV-2 vectors. It is likely that 
more vector is taken up by some structures due to the density of  their projections near the injection site. This 
is likely one of  the reasons that when CAV-2 vectors are injected into the striatum they efficiently infect DA 
neurons in the SN. Because the approximately 100-nm neutral-charged CAV-2 capsid (53) poorly diffuses 
in the brain parenchyma, it is likely that neurons are capable of  continually taking up vector particles for an 
extended period, possibly for several days. In addition, axonal and synaptic CAR levels may also influence 
vector uptake from many regions and neuron subtypes. The transcriptional changes after HD-GFP injection 
were unique for each structure and at each time point, suggesting a dynamic process influenced by vector 
transport. The initial innate immune response is consistent with in vitro data obtained using human mid-
brain neuroprogenitors following HD-GFP infection (32). However, long-term transgene expression demon-
strates that this transcriptional response does not lead to a notable adaptive immune response. Indeed, the 
transcriptional response at 28 days after injection suggested an evolution from an innate immune response 
toward tolerance. An adaptive response would upregulate IgMs, which have important roles in primary 
defense mechanisms; immunoglobulin λ-like polypeptide (IGLL3); HLA-DQA1 and HLA-DRB1, belong-
ing to MHC II complex; and IGHA1, the major Ig class playing a role in the defense against local infection. 
By contrast, tolerance involves an upregulation of  HLA-G, which is involved in antigen presentation and 
mediates protection against NK cells, cytotoxic T lymphocytes, and macrophages. Together, these data are 
consistent with the long-term CAV-2 vector–mediated transgene expression observed in the NHP brain. These 
data also set the stage for transcription-based analyses of  the cell autonomous and nonautonomous effect of  
LRRK2G2019S expression by neurons in vivo. For example, characterizing the transcriptional networks induced 
by LRRK2G2019S in DA neurons of  the SN could help identify therapeutic targets, as it has recently done with 
the PBX1 transcriptional network impaired in a mouse model of  PD (54).
In conclusion, our results have notable fundamental and clinical implications in the context of  model-
ing, preventing, or treating PD. While this study was focused on PD, numerous diseases may be amendable 
to modeling using CAV-2 vectors, regardless of  whether they affect specific nuclei or the entire brain.
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Methods
Animals
The M. murinus colony is housed at the primate facility at the University of  Montpellier (license approval 
34-05-026-FS). All procedures were in compliance with the rules of  the European Community Council Direc-
tive (2010/63/EU) for the care and use of  laboratory animals. Forty-seven animals were used in this study.
Vectors
Construction, purification, and storage of  HD-GFP, a HD CAV-2 vector expressing GFP, have been pre-
viously described (16). Codon-optimized LRRK2G2019S cDNA, tagged at the N-terminus with a 3×FLAG 
epitope tag (initially provided by C. Ross, Johns Hopkins University, Baltimore, Maryland, USA) (55) is 
followed by an internal ribosome entry site sequence (IRES from pIRES, Clontech) and GFP, was cloned 
into a pGut-3 and then inserted into a pEJK25 containing the HD genomes as previously described (16). 
HD vectors used during this study were approximately 5 × 1011 physical particle (pp)/ml with an infec-
tious to pp ratio of  approximately 1:20.
Stereotaxic injections
Twenty-seven M. murinus (7 naive animals without injection, 6 control HD-GFP, 4 HD-LRRK2, and 
10 HD-LRRK2G2019S) were used for behavioral and/or biogenic amine measurement and neuropatho-
logical analysis. Animals were anesthetized with 80 mg/kg ketamine/10 mg/kg xylazine by intra-
muscular injections. The animals were positioned in the stereotactic frame, an incision was made in 
the scalp, and a small hole was drilled unilaterally in the skull according to coordinates in M. murinus 
brain atlas (56). Needles were connected to a 10-μl Hamilton syringe and inserted into the putamen 
using the following coordinates: anterior, 6.5 mm from intra-aural line; lateral, 3 mm and –7 mm 
dorsoventral relative to the skull surface (56). HD-GFP, HD-LRRK2, or HD-LRRK2G2019S (109 pp of  
each vector, approximately 2 μl) was injected at a rate of  0.5 μl/min. The needle was left in place for 
additional 5 minutes before being slowly withdrawn. The skin was sterile sutured, and the M. murinus 
were monitored until they recovered from anesthesia. After surgery, primates were isolated in cage 
with food and water ad libitum.
Biodistribution study
Approximately 1 × 109 pp of  HD-GFP were injected into the right caudate nucleus (anterior to inter-aural 
zero, +4.5 mm; lateral, +1.7 mm; ventral, –4.5 mm). Mock-treated animals were injected with carrier (PBS 
without Ca++/Mg++ and 10% glycerol) using mirror coordinates in the left hemisphere to control for surgery 
and injections. After analyses, we found that using these coordinates in a couple of  female M. murinus that 
some vector was deposited in the lateral ventricle. After injections, the NHPs were isolated in ventilated 
cages with food and water ad libitum, checked twice a day for 3 days, and checked then daily for the dura-
tion of  the protocol. The vast majority of  animals appeared to recover completely from the surgery within 
24 hours, and all recovered by 48 hours. All animals retained their pre-op weight and ate normally by 24 
hours. All animals were sacrificed on the planned dates (Table 1).
Transcriptome analysis
Twelve 1-year-old female M. murinus were used for transcriptome experiments: 4 animals were used as 
sham-operated controls, 4 animals were injected with 109 pp of  HD-GFP in the right and left caudate 
nuclei  (mirror coordinates) and killed 1 day after injection, and 4 animals were injected in the right and left 
caudate nuclei and sacrificed 28 days after injection. After injections, primates were isolated in ventilated 
cages with food and water ad libitum. After euthanasia, each brain was cut in half  along the midline. The 
right and the left hemispheres were dissected in 25- to 30-mg fragments corresponding to the principal ana-
tomical regions and then were flash-frozen and temporarily stored at –80°C. All animals were sacrificed on 
the planned dates (Table 1).
RNA extraction and microarrays
Six regions were assayed: the right and left frontal cortices, the right and left striata, and the right and 
left midbrain. Total RNA was extracted from each region (25–30 mg) using the RNeasy Mini Kit (Qia-
1 4insight.jci.org   https://doi.org/10.1172/jci.insight.98202
R E S E A R C H  A R T I C L E
gen) according to the manufacturer’s protocol. The quality of  each purified RNA sample was checked 
using a NanoDrop Agilent BioAnalyzer (Agilent Technologies). Gene expression was detected by 
hybridization with human genome gene chips using an Affymetrix HG133 Plus 2. The processing and 
the data analysis of  the brain samples were previously described (22). Briefly, total RNA was extracted 
from each brain sample and prepared for hybridization with the gene chips according to the manu-
facturer’s protocol and using Microarray Affymetrix Suite 5.0 to normalize and analyze the intensity 
value of  each probe set. The primary expression files (*.cel) and (*.xls) are available at the GEO/NCBI 
repository (accession GSE102640, GSE102708, and GSE102709). Affymetrix microarray data were 
processed at the Microarray Core Facility of  the Institute of  Research of  Biotherapy of  Montpellier. 
Data were analyzed with the significance analysis of  microarrays (SAM) method (57), which calculat-
ed a q value, i.e., the lowest false discovery rate, according to the Δ cutoffs. The differential expression 
of  genes was also assessed by using ANOVA, Student’s 1-tailed t test, and PCA with the “R” software. 
The gene transcripts were assumed present in the brain sample when they were detected at least 3 
times in all the brain samples (58).
Gene profiling and biological functions and pathways
The gene expression profile of  each brain region (frontal cortex, striatum, and midbrain) and at the 2 
time courses (1 and 28 days) were established using centered Pearson’s correlation (https://www.r-proj-
ect.org/) and the Cluster and Treeview software programs (59). The involvement of  the differentially 
expressed genes in biological functions, cell activities, and signaling pathways was assessed using the 
following databases: Ensembl (http://www.ensembl.org/index.html), Uniprot (https://www.uniprot.
org/), Gene Ontology (http://www.geneontology.org/), KEGG (https://www.genome.jp/kegg/), and 
NCBI (https://www.ncbi.nlm.nih.gov/). The biological functions and pathways were also analyzed with 
the QIAGEN Ingenuity Pathway Analysis software (IPA; https://www.qiagenbioinformatics.com/).
Biodistribution of HD-GFP
Tissue collection, preparation, and analysis. Primates were anesthetized with ketamine (80 mg/kg) and per-
fused transcardially with heparinized saline (0.9%) followed by 4% PFA in PBS, pH 7.4. Brains were 
post-fixed in 4% PFA and soaked in 30% sucrose in PBS, pH 7.4, at 4°C for at least 24 hours. Brains 
were embedded in OCT and cut rostrocaudally. One 50-μm-thick section and then three 16-μm-thick 
sections were cut. The 50-μm-thick sections were mounted with Vectashield H-1000 (AbCys) to assay 
for GFP expression. The 16-μm-thick sections were used for colorations (hematoxylin/eosin, Luxol fast 
blue/cresyl violet, Kluver, and Barrera) and immunohistology. Primary antibodies included anti-NeuN 
(Chemicon, clone A60), anti-GFAP (Dako, Cytomation), anti-TH (MilliporeSigma, Ab152), anti-Tuj-1 
(R&D Systems, NL1195G), anti-CAR (R&D anti-human CXADR), and anti–α-synuclein antibody (T. 
Baron, Unité Maladies Neurodégénératives, Lyon, France). Synaptosomes were prepared as previously 
described (60). Floating 16-μm-thick sections were incubated with rabbit polyclonal anti-CAR (CAR-72) 
1:300 in PBS containing 3% BSA and 0.3% TX-100. Secondary antibodies, anti-mouse Alexa Fluor 647 
and anti-rabbit Alexa Fluor 555 (Molecular Probes), were diluted 1:300 in PBS containing 3% BSA and 
incubated for 1 hour at room temperature. After washing, floating sections were mounted in fluorescent 
mounting medium (DAKO).
Image acquisition and analysis. Images were acquired by using an upright Zeiss laser scanning confocal 
microscope (Axiovert 100M) with LSM 510 (version 2.5) software. GFP and Alexa Fluor 488 signals were 
excited at 488 nm, and fluorescent emission was collected using a BP 505- to 550-nm filter; rhodamine, 
Cy3, and Alexa Fluor 555 signals were excited at 543 nm and were collected using a BP 565- to 615-nm fil-
ter. Cy5 and Alexa Fluor 647 signals were excited at 600 nm and collected using a BP 640- to 660-nm filter. 
A spectral analysis was used to identify GFP-specific signals to avoid false positive signal.
Quantification of  neurons in the SNpc. Brains from noninjected animals were fixed in 4% PFA, embedded 
in OCT, and cut into 16- or 50-μm-thick serial sections. The 16-μm-thick sections were stained with Luxol 
fast blue/cresyl violet, and neurons in the SN were quantified using stereology software (Mercator, Explora 
Nova). The 50-μm-thick sections were incubated with an anti-TH antibody and revealed using a fluores-
cent secondary antibody. Unbiased stereological method Mercator Pro software was used every 120 μm to 
quantify DA neurons in the SNpc.
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Quantification of vector genomes
Brains were initially divided into left and right hemispheres. Each hemisphere was then dissected into fron-
tal, parietal, temporal, and occipital cortex; olfactory bulb; basal nuclei (including the striatum); thalamus and 
hypothalamus; midbrain; and cerebellum. The tissue was dissociated mechanically, and total DNA was purified 
using a NucleoBond kit (Macherey-Nagel). qPCR standards were generated using dilutions of vector DNA 
and mixed with genomic DNA extracted from a noninjected M. murinus brain. Two primer sets were used, 
GFP 5′-CAGAAGAACGGCATCAAGGT-3′ (base pairs 472–491) and 5′-CTGGGTGCTCAGGTAGT-
GG-3′ (base pairs 597–615), for vector amplification; additionally, GAPDH, 5′-ACAGTCCATGCCATCACT-
GCC-3′ and 5′-GCCTGCTTCACCACCTTCTTG-3′, and β-actin, 5′-CTGCAGAATTCCAAAGGAG-3′ and 
5′-CCAACCGTGAGAAGATGAC-3′, were used to normalize for genomic DNA copy number. qPCR was 
performed using the Light Cycler (Roche) and SYBR Green PCR kit (Qiagen) according to the manufacturers’ 
instructions. Data are expressed as a ratio to the genomic copies of GAPDH or β-actin.
Behavior analyses
Prior to injections, the animals were trained to perform the 3 motor tasks. We considered the performance before 
injection as the basal level (100%). Behavior analyses were performed every week for 6 months after injection.
Hourglass test. This task was used to evaluate quantitatively the animal’s righting reflex as a measure 
for rigidity analogous to axial motor behavior (61). The animal was placed in a narrow Plexiglas cylinder 
(6 × 18 cm). One trial consisted of  one natural 180-degree turn of  the cylinder. After 30 seconds, a new 
trial started by turning the cylinder again. A test consisted of  5 subsequent trials. Animals were always 
turned upright after 30 seconds (e.g., when they had not turned upright). We measured the time taken by 
the M. murinus to return to the upright position. Maximum time noted was 30 seconds (if  animals did not 
turn upright at all). The mean of  the 3 fastest turns was used for the analysis. Because of  the individual 
variability, a recovery index was calculated for each animal.
Tower test. This task consisted of  a tower with 6 levels of  rungs, where the M. murinus have to jump from 
the ground to the seventh level with increasing difficulty. This test quantifies the animal jumping behavior 
as a measure of  akinesia (61). The tower (35 × 35 × 180 cm) has a transparent Plexiglas front. It contains 6 
levels of  horizontal crossbars with an increasing distance varying from 10 to 50 cm to access the nest box. A 
camera was placed in front of  the tower for video analysis. The M. murinus was placed in front of  a sliding 
door at the bottom of  the tower. During each test the mouse lemur could freely move around the 6 levels for 
5 minutes. To motivate the animal, a reward was placed into the nest box. All animals were habituated to 
the tower before testing. A masked observer recorded the time needed to get into the nest box.
Six-tube task. This task measures the unconstrained exploration of its peripersonal space (62). For each trial, 
the M. murinus was required to search for and retrieve a food reward (a raisin) that was placed inside 1 of the 6 
tubes that were presented to the animal in a horizontal array. The animals had to jump on a small platform to 
reach the reward. The latency to retrieve the reward was recorded. Once the reward had been retrieved, or 30 
seconds had passed, the array of tubes was removed and another tube was baited. The task consisted of a total 
of 30 trials, with the location of the reward changing in a fixed random order, such that each tube was baited a 
total of 5 times. The M. murinus had been pretrained on this task and was free to use either hand. The pretreat-
ment score consisted of the time to remove all the rewards. Hand preference was also determined before surgery.
Histology
After the 6-month behavioral follow-up, the M. murinus were deeply anesthetized with ketamine (80 mg/kg) and 
perfused with saline followed by 4% PFA in 0.1 M phosphate buffer (pH 7.4). After post-fixation for 12 hours in 
4% PFA and cryoprotection in 30% sucrose solution, brains were cut into 40-μm-thick coronal sections.
Immunohistochemistry and quantitative analysis
Coronal sections (40 μm thick) from brains were prepared and processed for immunohistochemistry with 
rabbit anti-TH antibody (Institute Jacques Boy) and anti-LRRK2 antibody (Abcam, ab133474), anti-tau-
pSer396 (Novus Biologicals, NB100-92652), anti–α-synuclein (pS129) (Abcam, ab59264), anti-BRCA1 (San-
ta Cruz Biotechnology, SC642), and anti-Iba1 (Wako, NCNP24) (63). Briefly sections were quenched of  
endogenous peroxidase activity, permeabilized, and incubated with primary antibodies. Sections were pro-
cessed with biotinylated anti-rabbit IgG or anti-mouse IgG antibodies and avidin-biotin complex coupled 
to horseradish peroxidase (Vectastain ABC, Vector Laboratories) and visualized with 3,3′-diaminobenzi-
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dine reagent (Vector Laboratories). Sections were mounted on Superfrost slides, dehydrated with increasing 
ethanol concentrations and xylene, and then covered using Permount (Thermo Fisher Scientific). Mercator 
pro software was used on every sixth section, a sampling adapted to the studied structure to count TH+ 
neurons in the left and right SNpc. Analyses was performed by a masked observer.
Reagent availability
CAV-2 vectors are available via the nonprofit plateforme de vectorologie de Montpellier.
Statistics
Data distribution and within-group variation were preliminarily assessed to guide our methodological 
choices. Nonparametric tests Kruskal-Wallis and Dunn’s multiple comparison tests were used to com-
pared the 3 unmatched groups HD-GFP, HD-LRRK2, and HD-LRRK2G2019S, and comparison of  contra-
lateral and injected sides was added for each group for dopamine data. Changes were considered signifi-
cant when P < 0.05. Data were plotted as mean ± SEM. During behavioral tests, animals that refused to 
perform the tests were not included for analyses. For quantitative TH analysis, 2 animals were excluded 
because entire the brain sections were not available. All statistical tests were verified by the bioinformatics 
service at CNRS BioCampus (SERANAD, http://http://www.igmm.cnrs.fr/en/service/service-danal-
yse-de-donnees-biologiques-complexes/).
Study approval
The studies in animals were reviewed and approved by the ethical committee of  the Languedoc-Roussillon, 
France (CEEA-LR-1013, -1014, and -1015).
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